Logo image of WVE

WAVE LIFE SCIENCES LTD (WVE) Stock Fundamental Analysis

NASDAQ:WVE - Nasdaq - SG9999014716 - Common Stock - Currency: USD

10.57  -0.66 (-5.88%)

After market: 10.82 +0.25 (+2.37%)

Fundamental Rating

2

Taking everything into account, WVE scores 2 out of 10 in our fundamental rating. WVE was compared to 192 industry peers in the Pharmaceuticals industry. The financial health of WVE is average, but there are quite some concerns on its profitability. WVE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year WVE has reported negative net income.
WVE had a negative operating cash flow in the past year.
WVE had negative earnings in each of the past 5 years.
In the past 5 years WVE always reported negative operating cash flow.
WVE Yearly Net Income VS EBIT VS OCF VS FCFWVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

WVE has a Return On Assets (-39.75%) which is in line with its industry peers.
The Return On Equity of WVE (-95.32%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -39.75%
ROE -95.32%
ROIC N/A
ROA(3y)-63.5%
ROA(5y)-62.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WVE Yearly ROA, ROE, ROICWVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

WVE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WVE Yearly Profit, Operating, Gross MarginsWVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
WVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
WVE Yearly Shares OutstandingWVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
WVE Yearly Total Debt VS Total AssetsWVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

WVE has an Altman-Z score of -0.60. This is a bad value and indicates that WVE is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.60, WVE perfoms like the industry average, outperforming 51.04% of the companies in the same industry.
WVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.6
ROIC/WACCN/A
WACC9.69%
WVE Yearly LT Debt VS Equity VS FCFWVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

WVE has a Current Ratio of 1.90. This is a normal value and indicates that WVE is financially healthy and should not expect problems in meeting its short term obligations.
WVE has a Current ratio (1.90) which is in line with its industry peers.
WVE has a Quick Ratio of 1.90. This is a normal value and indicates that WVE is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of WVE (1.90) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.9
WVE Yearly Current Assets VS Current LiabilitesWVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

WVE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.64%.
EPS 1Y (TTM)-43.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%213.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%188.24%

3.2 Future

The Earnings Per Share is expected to grow by 30.58% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 57.44% on average over the next years. This is a very strong growth
EPS Next Y-34.95%
EPS Next 2Y-12.69%
EPS Next 3Y18.21%
EPS Next 5Y30.58%
Revenue Next Year29.69%
Revenue Next 2Y31.47%
Revenue Next 3Y42.62%
Revenue Next 5Y57.44%

3.3 Evolution

WVE Yearly Revenue VS EstimatesWVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
WVE Yearly EPS VS EstimatesWVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for WVE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for WVE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WVE Price Earnings VS Forward Price EarningsWVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WVE Per share dataWVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

WVE's earnings are expected to grow with 18.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.69%
EPS Next 3Y18.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for WVE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WAVE LIFE SCIENCES LTD

NASDAQ:WVE (3/5/2025, 8:00:02 PM)

After market: 10.82 +0.25 (+2.37%)

10.57

-0.66 (-5.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-04 2025-03-04/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners83.58%
Inst Owner Change8.3%
Ins Owners0.5%
Ins Owner Change0.67%
Market Cap1.61B
Analysts82.67
Price Target23.37 (121.1%)
Short Float %7.39%
Short Ratio10.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42%
Min EPS beat(2)-64.24%
Max EPS beat(2)-19.77%
EPS beat(4)1
Avg EPS beat(4)-15.14%
Min EPS beat(4)-64.24%
Max EPS beat(4)34.48%
EPS beat(8)3
Avg EPS beat(8)-57.91%
EPS beat(12)4
Avg EPS beat(12)-40.74%
EPS beat(16)6
Avg EPS beat(16)-29.32%
Revenue beat(2)0
Avg Revenue beat(2)-82.36%
Min Revenue beat(2)-144.85%
Max Revenue beat(2)-19.88%
Revenue beat(4)1
Avg Revenue beat(4)-41.44%
Min Revenue beat(4)-144.85%
Max Revenue beat(4)44.87%
Revenue beat(8)3
Avg Revenue beat(8)-3.13%
Revenue beat(12)3
Avg Revenue beat(12)-29.64%
Revenue beat(16)4
Avg Revenue beat(16)-17.73%
PT rev (1m)0%
PT rev (3m)1.35%
EPS NQ rev (1m)4.21%
EPS NQ rev (3m)4.21%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)4.98%
Revenue NQ rev (3m)4.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.07
P/FCF N/A
P/OCF N/A
P/B 10.78
P/tB 10.78
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.35
BVpS0.98
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.75%
ROE -95.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.5%
ROA(5y)-62.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.66%
Cap/Sales 2.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.9
Altman-Z -0.6
F-Score4
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)16.83%
Cap/Depr(5y)23.73%
Cap/Sales(3y)13.2%
Cap/Sales(5y)14.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%213.33%
EPS Next Y-34.95%
EPS Next 2Y-12.69%
EPS Next 3Y18.21%
EPS Next 5Y30.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%188.24%
Revenue Next Year29.69%
Revenue Next 2Y31.47%
Revenue Next 3Y42.62%
Revenue Next 5Y57.44%
EBIT growth 1Y-63.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-99.25%
EBIT Next 3Y-36.52%
EBIT Next 5YN/A
FCF growth 1Y-38.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.72%
OCF growth 3YN/A
OCF growth 5YN/A